Consort Medical plc (CSRT) Receives GBX 1,223.25 Consensus PT from Analysts
Consort Medical plc (LON:CSRT) has been given a consensus rating of “Buy” by the six research firms that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is GBX 1,223.25 ($16.90).
CSRT has been the subject of a number of research reports. Numis Securities upgraded Consort Medical to an “add” rating and set a GBX 1,333 ($18.42) target price for the company in a report on Thursday, February 8th. Shore Capital reiterated a “buy” rating on shares of Consort Medical in a report on Tuesday, December 5th. Stifel Nicolaus reiterated a “buy” rating and set a GBX 1,250 ($17.27) target price on shares of Consort Medical in a report on Thursday, November 9th. Finally, N+1 Singer lowered Consort Medical to a “hold” rating in a research report on Tuesday, December 5th.
Shares of Consort Medical (LON:CSRT) traded up GBX 18 ($0.25) during trading hours on Friday, hitting GBX 1,202 ($16.61). The stock had a trading volume of 2,188 shares, compared to its average volume of 24,464. Consort Medical has a 1-year low of GBX 976.09 ($13.49) and a 1-year high of GBX 1,230 ($16.99). The stock has a market cap of $592.38 and a PE ratio of 3,005.00.
Consort Medical Company Profile
Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.
Receive News & Ratings for Consort Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical and related companies with MarketBeat.com's FREE daily email newsletter.